Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1072205 | 0.86 | GPR119 (0.60) | GPR119SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL386217 | 0.80 | GPR119 (0.80) | GPR119 | |
| SCHEMBL389444 | 0.78 | GPR119 (0.77) | GPR119 | |
| SCHEMBL389377 | 0.73 | GPR119 (0.80) | GPR119 | |
| SCHEMBL389784 | 0.71 | GPR119 (0.81) | GPR119 | |
| SCHEMBL387931 | 0.71 | GPR119 (0.78) | GPR119 | |
| SCHEMBL390610 | 0.70 | GPR119 (0.77) | GPR119SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL390350 | 0.70 | GPR119 (1.00) | GPR119 | |
| SCHEMBL390322 | 0.69 | GPR119 (0.74) | GPR119 | |
| SCHEMBL389864 | 0.68 | GPR119 (1.00) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-B1 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | ARENA PHARM INC (US) | 2011-01-12 | — | — | EP | disclosed |